Sickle Cell Drug
![EU Regulators Call for Withdrawal of Authorization for Novartis' Sickle Cell Drug Adakveo Following Phase 3 Setback](https://pharmtales.com/wp-content/uploads/2023/06/EU-Regulators-Call-for-Withdrawal-of-Authorization-for-Novartis-Sickle-Cell-Drug-Adakveo-Following-Phase-3-Setback-1.jpg)
EU Regulators Call for Withdrawal of Authorization for Novartis’ Sickle Cell Drug Adakveo Following Phase 3 Setback
SG Tylor
After the phase 3 trial of Novartis’ sickle cell disease drug, Adakveo, yielded disappointing results, regulators in Europe have revisited ...